DELIGASE Trademark

Trademark Overview

On Tuesday, March 31, 2020, a trademark application was filed for DELIGASE with the United States Patent and Trademark Office. The USPTO has given the DELIGASE trademark a serial number of 88855023. The federal status of this trademark filing is REGISTERED as of Tuesday, July 6, 2021. This trademark is owned by Nurix Therapeutics, Inc.. The DELIGASE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of biological and pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform
deligase

General Information

Serial Number88855023
Word MarkDELIGASE
Filing DateTuesday, March 31, 2020
Status700 - REGISTERED
Status DateTuesday, July 6, 2021
Registration Number6412399
Registration DateTuesday, July 6, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 4, 2020

Trademark Statements

Goods and ServicesResearch and development of biological and pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 7, 2020
Primary Code042
First Use Anywhere DateThursday, January 16, 2020
First Use In Commerce DateThursday, January 16, 2020

Trademark Owner History

Party NameNurix Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94158
Party NameNurix Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94158
Party NameNurix Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94158

Trademark Events

Event DateEvent Description
Tuesday, July 6, 2021REGISTERED-PRINCIPAL REGISTER
Wednesday, June 2, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, June 1, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, May 14, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 14, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 14, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 5, 2021TEAS EXTENSION RECEIVED
Wednesday, November 18, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 18, 2020NON-FINAL ACTION E-MAILED
Wednesday, November 18, 2020SU - NON-FINAL ACTION - WRITTEN
Thursday, October 29, 2020STATEMENT OF USE PROCESSING COMPLETE
Monday, October 12, 2020USE AMENDMENT FILED
Wednesday, October 28, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 12, 2020TEAS STATEMENT OF USE RECEIVED
Tuesday, September 29, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 4, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 4, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 15, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, July 2, 2020ASSIGNED TO LIE
Monday, June 29, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 29, 2020EXAMINER'S AMENDMENT ENTERED
Monday, June 29, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, June 29, 2020EXAMINERS AMENDMENT E-MAILED
Monday, June 29, 2020EXAMINERS AMENDMENT -WRITTEN
Friday, June 19, 2020ASSIGNED TO EXAMINER
Tuesday, April 7, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, April 3, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

deligase proprietary utilizing drug discovery platform diseases treat development biological pharmaceutical